ECONOMIC VALUE: Greater efficiency of care, with fewer office visits for patient and physician alike.5
CLINICAL OUTCOMES: In one study, CareLink systems use among patients with diabetes led to significant blood glucose (A1C) reductions.6 In one study for heart device patients who used the CareLink Network, the time from a clinically actionable event to when they were treated was 17.4 days less than heart device patients who didn't use remote monitoring, via the CareLink Network with automatic CareAlert® Notifications.7
SOCIETAL IMPACT: With chronic disease rates on the rise, CareLink systems give patients more ownership over managing their conditions to help relieve the burden on healthcare systems.
For people with chronic diseases like diabetes and heart conditions, managing their condition is a lifelong collaboration with healthcare teams. We've made the process easier with our CareLink® systems, which allow patients with certain insulin pumps and heart devices to download information captured by their device and transfer that data via a secure server to the CareLink website. This creates a seamless link so everyone has the information needed to make smart, timely healthcare decisions. Here are two examples:
A key goal in managing chronic disease is to catch new developments early — so doctors and patients can make medical or lifestyle changes before conditions worsen and require more complex and costly treatments. Heart failure is a prime example. It's the single most costly medical expense in the Unites States, according to the American Heart Association, and results in more than 1.1 million hospital admissions every year.1,2
Many of our heart devices help failing hearts pump better, but a patient's condition can still worsen. One sign of worsening heart failure is fluid build-up in the thoracic cavity.3 So we developed OptiVol® Fluid Status Monitoring and built it into many of our cardiac devices to detect fluid build-up.4 If a heart failure patient's fluid build-up reaches a certain threshold, the doctor sees this trend on a report and identifies those patients at risk for worsening heart failure. The doctor can recommend diet adjustments or alter medications.
OptiVol Monitoring is not intended to replace assessments that are part of standard clinical practice.
The Future Goal
Today, our Carelink® system for diabetes allows patients with our insulin pump and continuous glucose monitoring system (CGM) to see glucose trend reports and share them with their care teams. Tomorrow, our goal is to use the CareLink system to potentially give everyone on a patient's care team access to real-time glucose therapy information.
We're currently in early-stage development, with the goal of having information sent in real time from a patient's CGM-equipped insulin pump to caregivers and medical professionals, which could help avoid potentially life-threatening high or low glucose conditions, and help better manage the patient's diabetes.
This concept is in very early development; its success and risk have not been evaluated.
CareLink systems give device patients and their healthcare teams important device- and health-related information to better manage their chronic disease.
- ECONOMIC VALUE: Greater efficiency of care, with fewer office visits for patient and physician alike.5
- CLINICAL OUTCOMES: In one study, CareLink systems use among patients with diabetes led to significant blood glucose (A1C) reductions.6 In one study for heart device patients who used the CareLink Network, the time from a clinically actionable event to when they were treated was 17.4 days less than heart device patients who didn't use remote monitoring, via the CareLink Network with automatic CareAlert® Notifications.7
- SOCIETAL IMPACT: With chronic disease rates on the rise, CareLink systems give patients more ownership over managing their conditions to help relieve the burden on healthcare systems.
References: 1Medicare Provider Analysis and Review (MEDPAR) Limited Data Set, 2008. 2Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. February 23, 2010;121(7):e46-215. 3Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481. 4Yu CM, Wang L, Chau, E. et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9, 2005;112(6):841-848. 5Crossley GH, Boyle A, Berman B. Patient and caregiver burden of following implantable cardioverter defibrillators. HRS 2008. 6Corriveau EA, Durso PJ, Kaufman ED, et al. Effect of CareLink, and internet-based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatric Diabetes 2008: 9(part II): 360-366. 7Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH, and CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) Trial: The Value of Wireless Remote Monitoring With Automatic Clinician Alerts. J Am Coll Cardiol. March 8, 2011.